1-[(8R,9S,10R,13S,14S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]benzimidazole

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 1-[(8R,9S,10R,13S,14S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]benzimidazole
• 化学式: C₂₆H₃₂N₂
• 分子量: 372.5
• InChiKey: MJPIIDZOJJQIEY-HKGZJRCASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  28
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ANDROGEN RECEPTOR DOWN-REGULATING AGENTS AND USES THEREOF
  申请人：University of Maryland, Baltimore

  公开号：EP2968370A1

  公开（公告）日：2016-01-20
• NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY
  申请人：University of Maryland, Baltimore

  公开号：EP2991644A2

  公开（公告）日：2016-03-09
• [EN] ANDROGEN RECEPTOR DOWN-REGULATING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE DIMINUTION DU RÉCEPTEUR DES ANDROGÈNES ET LEURS UTILISATIONS
  申请人：UNIV MARYLAND BALTIMORE OFFICE OF TECHNOLOGY TRANSFER

  公开号：WO2014153215A1

  公开（公告）日：2014-09-25

  The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.
• [EN] NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY<br/>[FR] COMPOSÉS NON-STÉROÏDIENS ET STÉROÏDIENS PUISSANTS EN TERMES DE RÉGULATION À LA BAISSE DU RÉCEPTEUR DES ANDROGÈNES ET D'ACTIVITÉ CONTRE LE CANCER DE LA PROSTATE
  申请人：UNIV MARYLAND

  公开号：WO2014165815A2

  公开（公告）日：2014-10-09

  Nonsteroid and steroid compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant, induce apoptosis and inhibit proliferation of inhibiting proliferation and migration of androgen sensitive cancer cells. The steroid compounds and nonsteroid compounds may be agents for the prevention and/or treatment of cancer, including prostate cancer, castration resistant prostate cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, benign prostatic hyperplasia (BPH), Kennedy's disease, androgenetic alopecia, breast cancer, androgen-insensitive syndrome, and spinal and bulbar muscular atrophy.